Recombinant lentiviral expression vector, recombinant cell and application of recombinant lentiviral expression vector in in-vitro culture of tissue engineering epidermis
Through recombinant lentiviral expression vectors and recombinant cell technology, the proliferation and secretion of melanocytes are promoted, and the pain and low efficiency of traditional epidermal transplant surgery is solved, the rapid proliferation and uniform distribution of melanocytes are achieved, and the effect of vitiligo treatment is significantly improved. .
Patent Information
- Application Number
- CN202411242620.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-05
- Publication Date
- 2024-11-15
AI Technical Summary
Traditional epidermal transplantation programs require multiple surgeries when treating vitiligo, and patients with large areas of white spots need to take multiple skin retrievals. The process is painful, and the number of melanocytes and secretion ability affect the treatment effect. It is urgent to develop methods to rapidly proliferate melanocytes.
Recombinant lentivirus expression vector pLenti-EF1a-C-IL1α-P2A-IL15-mGFP was used to construct recombinant cells by inserting the IL1α-P2A-IL15 fusion gene into the vector. mGFP, as a trophoblast cell, is used for the culture of tissue engineering epidermis, inhibits fibroblast growth and promotes melanocyte proliferation and secretion.
The rapid proliferation and uniform distribution of melanocytes have been achieved, which significantly improves the pigment recovery effect of the white spot area, has good clinical application prospects, and provides a basis for research.
Smart Images

Figure CN118956972A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology, and specifically relates to a recombinant lentiviral expression vector, a recombinant cell and applications thereof in tissue engineering epidermal culture. Background Art
[0002] Vitiligo is a skin disease with unknown pathogenesis. One in every 200 people in the world is affected by vitiligo. Several potential pathogenesis of vitiligo have been proposed, including autoimmunity, neurohumoral factors and autocytotoxicity. Vitiligo may be caused by a variety of factors. The affected parts cover the whole body, and are common on the face, trunk and limbs. Vitiligo is a skin disease with depigmentation caused by local destruction of melanocytes. The affected area is a white spot on the skin with clear boundaries. The most common clinical features are skin color loss, whitening, clear boundaries and no subjective symptoms. At present, the main treatment options for vitiligo are drugs, ultraviolet irradiation and epidermal transplantation. The traditional epidermal transplantation scheme is to remove a part of normal skin from healthy skin and then transplant it to the diseased white spot area. The transplantation ratio is generally less than 1:1. Patients with large areas of white spots need to repeat the transplantation operation many times, which is a painful process.
[0003] The culture of tissue-engineered epidermis can achieve the expansion of skin area from small to large, which solves the problem of large-area skin transplantation. Tissue-engineered epidermis is mainly composed of keratinocytes and melanocytes. Among them, the number of melanocytes and their ability to secrete melanin are crucial, which directly affects the effect of vitiligo recovery. Therefore, it is urgent to develop a method that can rapidly proliferate melanocytes. Summary of the invention
[0004] The purpose of the present invention is to provide a recombinant lentiviral expression vector, a recombinant cell and the use thereof in in vitro culture of tissue engineering epidermis.
[0005] To achieve the above object, the present invention adopts the following technical solution: A recombinant lentiviral expression vector pLenti-EF1a-C- IL1α-P2A-IL15 -mGFP, the recombinant lentiviral expression vector pLenti-EF1a-C- IL1α-P2A-IL15 -mGFP is the fusion gene IL1α-P2A-IL15 Inserted into the restriction site BamHI / NotI of the vector pLenti-EF1a-C-mGFP; The fusion gene IL1α-P2A-IL15 The nucleotide sequence is shown in SEQ ID NO.1.
[0006] The fusion gene IL1α-P2A-IL15 The amino acid sequence of the encoded protein is shown in SEQ ID NO.2.
[0007] A recombinant cell, the recombinant cell comprising the recombinant lentiviral expression vector pLenti-EF1a-C- IL1α-P2A-IL15 -mGFP.
[0008] The recombinant cell is 3T3-pLenti-EF1a-C- IL1α-P2A-IL15 -mGFP, which is obtained by transfecting the above-mentioned recombinant lentiviral expression vector into 3T3 cells.
[0009] Use of the above-mentioned recombinant lentiviral expression vector and the above-mentioned recombinant cell in in vitro culture of tissue engineering epidermis.
[0010] A method for culturing tissue engineering epidermis in vitro, the method using the above-mentioned recombinant cell 3T3-pLenti-EF1a-C- IL1α-P2A-IL15 -mGFP as trophoblast cells.
[0011] The present invention has the following advantages: The recombinant cell 3T3-pLenti-EF1a-C- IL1α-P2A-IL15 -mGFP is used as trophoblast cells in the culture of tissue engineering epidermis, which can not only effectively inhibit the growth of fibroblasts, but also secrete IL1α and IL15 factors to promote melanocyte proliferation and melanin secretion. It has good prospects for clinical application and also provides a research basis for studying the role of IL1α and IL15 factors in promoting melanocyte proliferation and melanin secretion. BRIEF DESCRIPTION OF THE DRAWINGS
[0012] Figure 1 : Schematic diagram of the structure of the fusion gene.
[0013] Figure 2 : Schematic diagram of the structure of the recombinant lentiviral expression vector.
[0014] Figure 3 : Enzyme digestion results of recombinant lentiviral expression vector.
[0015] Figure 4 : Schematic diagram of fluorescence microscopy observation after lentivirus infection of 3T3 cells.
[0016] Figure 5 : IL1α and IL15 protein expression results.
[0017] Figure 6 :3T3-pLenti-EF1a-C- IL1α-P2A-IL15 Schematic diagram of the fusion process of two groups of tissue-engineered epidermal cells using -mGFP and 3T3 cells as trophoblasts.
[0018] Figure 7 :3T3-pLenti-EF1a-C- IL1α-P2A-IL15 Schematic diagram of the complete fusion of two groups of tissue-engineered epidermal cells with -mGFP and 3T3 cells as trophoblasts.
[0019] Figure 8 : Schematic representation of tissue engineering epidermal peeling.
[0020] Fig. 9 :3T3-pLenti-EF1a-C- IL1α-P2A-IL15 Schematic diagram of DOPA staining of two groups of tissue-engineered epidermis with -mGFP and 3T3 cells as trophoblasts.
[0021] Fig.10 :3T3-pLenti-EF1a-C- IL1α-P2A-IL15 Schematic diagram of HE staining of two groups of tissue-engineered epidermis with -mGFP and 3T3 cells as trophoblasts. DETAILED DESCRIPTION
[0022] In order to make the contents of the present invention easier to understand, the technical solution of the present invention is further described below in conjunction with specific implementation methods, but the present invention is not limited thereto.
[0023] The reagents and raw materials used in the present invention can be purchased from the market. The pLenti-EF1a-C-mGFP plasmid was purchased from ORIGENE, item number PS100084; the transfection reagent FuGENE®6 was purchased from FuGENE, item number E2691; the trypsin inhibitor was purchased from Gibco, item number R002100; and the dispase was purchased from Yuanye, item number S25046. Unless otherwise specified, the preparation methods in the present invention are all conventional preparation methods and will not be described in detail.
[0024] DMEM complete medium with FBS: 89 mL DMEM complete medium + 10 mL FBS + 1 mL 100X penicillin-streptomycin-glutamine solution (Gibco).
[0025] Example 1 pLenti-EF1a-C- IL1α-P2A-IL15 -mGFP recombinant lentiviral expression vector construction process and lentiviral packaging (1) IL1α Gene P2A and IL15 Gene ligation to form a fusion gene encoding IL1α-P2A-IL15 fusion protein ( Figure 1 ), the nucleotide sequence of the fusion gene is shown in SEQ ID NO.1, and the nucleotide sequence of the IL1α-P2A-IL15 fusion protein is shown in SEQ ID NO.2.
[0026] Shanghai Bioengineering was commissioned to synthesize the fusion gene encoding IL1α-P2A-IL15 fusion protein and insert it into the BamHI / NotI restriction site of the pLenti-EF1a-C-mGFP vector to construct the recombinant expression vector pLenti-EF1a-C- IL1α-P2A-IL15 -mGFP ( Figure 2 ). Place the EP tube containing 100 μL DH5α competent cells in an ice bath, and add 2 μL of the recombinant expression vector pLenti-EF1a-C- IL1α-P2A-IL15 -mGFP, gently mix and place in an ice bath for 30 min, then place in a 42 ℃ water bath for heat shock for 90 s, and immediately place in an ice bath for cooling for 5 min after heat shock. Add 400 μL of LB liquid medium without resistance to the EP tube, mix and place in a shaker (37 ℃, 45 r / min) for 1 h to restore the normal growth of DH5α competent cells and express the chloramphenicol antibiotic resistance gene encoded by the plasmid. Spread 400 μL of LB liquid medium containing the above DH5α competent cells on an LB plate containing 30 ug / mL chloramphenicol, and culture in a 37 ℃ incubator for 48 h to obtain positive clones. Pick a single colony and transfer it to 5 mL of LB liquid medium containing 30 ug / mL chloramphenicol, culture in a 37 ℃ incubator for 16 h until the bacterial solution is obviously turbid, take 5 mL of the culture solution for plasmid extraction, double enzyme digestion with BamHI and NotI, and the digestion product is detected after 1% agarose gel electrophoresis. The results of enzyme digestion identification are as follows Figure 3 As shown, there is an amplified band between 1000 and 2000 bp, which is consistent with the designed fusion gene size of about 1370 bp, indicating that the recombinant expression vector was successfully constructed.
[0027] (2) Lentiviral packaging 293T cells were revived with DMEM complete medium containing FBS and expanded and cultured in a 37°C, 5% CO2 incubator. When the cell growth density was about 80-90%, the original cell culture medium was discarded, and the cells were washed twice with sterile PBS. Then, 2 ml of 0.25% trypsin was added to digest in a 37°C incubator for 1 min. When the cells gradually became round under the microscope, 4 ml of DMEM complete medium containing FBS was added to terminate the digestion. The liquid was collected in a sterile centrifuge tube and mixed well. A small amount was taken for cell counting. The remaining cell suspension was centrifuged at 1000 rpm for 5 min, the supernatant was discarded, and the cell pellet was collected; fresh DMEM complete medium was added to the cell pellet to resuspend it, and 100 uL of 2×10 4 293T cells were seeded in 96-well plates at a density of 100 cells / well and cultured in a 37°C, 5% CO2 incubator.
[0028] After 24 hours of culture, transfection was performed when the confluence of 293T cells reached 50%-80%. DMEM complete medium and transfection reagent FuGENE®6 were restored to room temperature, 80 uL DMEM complete medium and 15 uL transfection reagent FuGENE®6 were added to a sterile EP tube, mixed and incubated at 37°C for 5 min, and then 5 uL of a mixture consisting of psPAX2 packaging plasmid, pMD2.G packaging plasmid and recombinant lentiviral expression vector (mass ratio of 2ug:1ug:2ug) was added, mixed immediately, incubated at room temperature for 15 min, and then transfected into 293T cells, and placed in a 37°C, 5% CO2 incubator for culture. After 24 hours, fresh DMEM complete medium was replaced and continued to be cultured. After 48 hours, the virus supernatant was collected, filtered with a 0.45 um filter, and then centrifuged at 1500 rpm for 10 min, the lentiviral supernatant was collected, and kept at -80°C for use.
[0029] Example 2 Lentivirus infection of 3T3 cells (1) 3T3 cells were cultured at 5×10 4 The cells were inoculated at a density of 100 / well in a 24-well cell culture plate, and 1 ml of lentiviral supernatant was added, and polybrene was added to a final concentration of 6 ug / ml, and the cells were incubated in a 37°C, 5% CO2 incubator for 24 h. Then 100ul of 0.25% trypsin was added for digestion, and the resulting cell suspension was centrifuged at 500 g for 5 min, the supernatant was discarded, the cell pellet was collected, and the cell pellet was resuspended in 1ml of fresh 3T3 cell culture medium (DMEM+5% platelet lysis solution), and the resulting cell suspension was transferred to a new 24-well plate, and cultured in a 37°C, 5% CO2 incubator for 3 days. After the cells are fully grown, they can be passaged and frozen.
[0030] (3) Detection of transduction efficiency by fluorescence microscopy 3T3 cells were infected with lentivirus and observed under a fluorescence microscope 24 h later. The results showed that the cells expressed green fluorescence with high fluorescence intensity ( Figure 4 ). This indicates that the lentivirus packaging was successful and the transfection efficiency was high. The recombinant cell line 3T3-pLenti-EF1a-C- IL1 α-P2A-IL15 -mGFP was successfully constructed and expressed at a high level, and can be used for subsequent experiments.
[0031] Example 3 Detection of IL1α and IL15 protein expression levels Two experimental groups were set up: the control group was 3T3 cells without lentivirus infection, and the experimental group was 3T3 cells infected with lentivirus. 2×10 510 cells and 2 ml of fresh 3T3 cell culture medium (DMEM + 5% platelet lysate), cultured in a 37°C, 5% CO2 incubator for 48 h, centrifuged at 500 g for 5 min, collected the supernatant, and measured the IL1α and IL15 protein content using an Elisa kit. The experimental steps are as follows: (1) Set up standard wells and sample wells, and add 50 μL of standard of different concentrations to each standard well.
[0032] (2) Add 50 μl of the sample to be tested to the sample well and nothing to the blank well.
[0033] (3) Except for the blank wells, add 100 μl of horseradish peroxidase-labeled detection antibody to each well of the standard well and sample well, seal the reaction wells with a sealing film, and incubate in a 37°C incubator for 60 min.
[0034] (4) Discard the liquid, pat dry on absorbent paper, add 350 μL of washing solution to each well, let stand for 1 min, shake off the washing solution, pat dry on absorbent paper, and repeat this washing process 5 times.
[0035] (5) Add 50 μl of substrate A and B to each well and incubate at 37°C in the dark for 15 min.
[0036] (6) Add 50 μL of stop solution to each well and measure the OD value of each well at a wavelength of 450 nm within 15 min.
[0037] Finally, the concentrations of IL1α and IL15 in the samples were calculated using the standard curve. Figure 5 As shown, compared with the control group, the levels of IL1α and IL15 proteins secreted by the experimental group increased significantly, indicating that 3T3 cells successfully infected with lentivirus can well express the fusion protein on the recombinant lentiviral vector.
[0038] Example 4 Cultivation and morphological observation of human tissue-engineered epidermis The tissue engineering epidermal culture medium formula used was as follows: 10 g / L human albumin, 10 mg / L human insulin, 6.5 mg / L human transferrin, 7.5 μg / L sodium selenite, 3 mg / L aminoethanol, 4 mM glutamine, 0.5 mg / mL cyclic adenosine monophosphate, 30 ng / mL human bone morphogenetic protein 4, 1 nM α-melanocyte stimulating hormone, 10 ng / mL hepatocyte growth factor, 1 μg / mL granulocyte macrophage colony stimulating factor, 0.6 μg / mL basic fibroblast growth factor, 50 μM stem cell growth factor, 2 mg / L triiodothyronine, 10 ng / mL epidermal growth factor, 0.5 μg / mL isoproterenol, 10 nM endothelin-1, 10 nM endothelin-3, 0.4 μg / mL hydrocortisone and 10 μM ROCK inhibitor Y-27632; wherein the DMEM / F12 culture medium is a mixture of DMEM and F12 in a volume ratio of 3:1.
[0039] (1) Preparation of trophoblast cells Before primary culture and subculture of tissue engineering epidermal cells, trophoblast cell recovery and MMC treatment should be performed. The experiment was divided into two groups, A and B. Group A was the experimental group, and the trophoblast cells used were 3T3-pLenti-EF1a-C- IL1α- P2A-IL15 -mGFP; Group B is the control group, and the trophoblast cells used are ordinary 3T3 cells. The specific operation steps are as follows: Resuscitate frozen trophoblast cells, prepare cell suspension, inoculate into trophoblast cell culture medium (DMEM + 5% platelet lysate), and adjust the density to 5×10 4 cells / mL, inoculated into six-well plates or 60 mm culture dishes, 2 mL per well of six-well plates, 4 mL per dish of 60 mm culture dishes, and cultured at 37°C. Three days later, when the cell confluence reached 90% under the microscope, 1 / 24 volume of MMC (initial concentration of MMC was 0.1 mg / mL) was added to the culture medium, and incubated in a 37°C incubator for 90 min. After incubation, the supernatant was discarded, washed twice with α-MEM medium, and then the corresponding volume of trophoblast cell culture medium was added.
[0040] (2) Isolation of human epidermal cells for tissue engineering A 3 cm × 3 cm piece of normal skin from the inner thigh of a human was taken and disinfected with 75% alcohol for 1 min, and then the connective tissue and adipose tissue were removed with scissors and forceps. Then, it was washed with normal saline for 7 times, the skin was cut into pieces with scissors, and 8 mL of 0.1wt% type I collagenase (215 U / mg) enzyme solution was added, and the skin was digested overnight at 37 °C shaking. On the second day, 2 mL of trypsin (Gibco) with a final concentration of 0.05 wt% was added, and the skin was digested at 37 °C shaking for 2 h. Subsequently, 2 mL of trypsin inhibitor was added to terminate the digestion, and the cell suspension was passed through a 70 μm cell sieve, centrifuged at 500 g for 5 min, the supernatant was discarded, the cell pellet was collected, and the cell pellet was resuspended in normal saline to obtain a human tissue engineering epidermal cell suspension, and samples were counted.
[0041] (3) Culture and observation of tissue-engineered epidermal cells The cell suspension was divided into two groups, A and B, and centrifuged at 500 g for 5 min. The supernatant was discarded and the cell pellet was collected. 5 The cells / well were inoculated into six-well plates containing two types of trophoblast cells treated with MMC, cultured at 37°C, and observed under a microscope every two days. The tissue engineering epidermal culture medium was replaced for the first time after four days of culture, and then changed every two days. When the keratinocyte clones were observed under the microscope to contain about 100-150 cells per clone, the subculture step could be performed. At this time, the morphology of the tissue engineering epidermal cells is as follows Figure 6 shown.
[0042] (4) Subculturing of tissue engineered epidermal cells Remove the culture medium, add 0.02 wt% EDTA to wash the cells twice, and then add 0.02wt% EDTA to incubate at 37 ℃ for 20 min. Then add 0.05 wt% trypsin to digest for 1-3 min, and then add an equal volume of trypsin inhibitor to terminate the digestion. Centrifuge at 500g for 5 minutes, discard the supernatant, collect the cell pellet, add tissue engineering epidermal culture medium to the cell pellets of groups A and B, and inoculate them into 60 mm culture dishes containing two types of trophoblast cells treated with MMC. Passage according to the ratio of 1 hole to 1 60 mm culture dish.
[0043] (5) Fusion of tissue-engineered epidermal cells After subculturing, the tissue engineering epidermal culture medium was changed every two days until the epidermal cells were completely fused. When the tissue engineering epidermal culture medium was changed every day, the epidermal cells began to grow in an overlapping manner and differentiated and thickened into a multi-layered epidermis, such as Figure 7 shown.
[0044] (6) Exfoliation of tissue-engineered epidermis Add dispase at a final concentration of 0.1 mg / mL to the culture medium, incubate at 37 °C for 15-20 min, peel the tissue-engineered epidermis from the culture dish from the edge to the middle with tweezers, wash twice with 1× PBS buffer (pH 7.2), transfer the epidermis to a new 60 mm culture dish, and perform DOPA staining and HE staining detection experiments.
[0045] like Figure 6 , 7 As shown, Group A is 3T3-pLenti-EF1a-C- IL1α-P2A-IL15 -mGFP was used as the trophoblast to culture tissue engineering epidermal cells, and ordinary 3T3 cells were used as the trophoblast to culture tissue engineering epidermal cells in group B. The growth status of human tissue engineering epidermal cells in groups A and B was good. During the process of keratinocytes forming large-scale clones, the trophoblast cells in group A gradually apoptosis and fall off. When the keratinocytes are completely fused, the trophoblast cells completely fall off and disappear. After the keratinocytes are fused into sheets, they begin to differentiate and thicken into multi-layered stratified epidermis. The trophoblast cells in group B did not fall off completely, but were stacked together and attached to the top of the epidermis. Figure 8 As shown, the skin flap has a certain thickness and is easy to peel off, and the skin flap is intact without damage after peeling.
[0046] Example 5 DOPA dyeing Part of the tissue-engineered epidermis obtained in Example 4 was cut out, washed twice with 1× PBS buffer (pH 7.2), fixed with 4% paraformaldehyde for 10 min, and then washed twice with 1× PBS buffer (pH 7.2), dried naturally for 2 h, and incubated at 37°C for 4-5 h. The cells were counted under a microscope. The results are as follows: Fig. 9 As shown, melanocytes in group A proliferated and were evenly distributed, with the number of cells exceeding 160 / mm 2 , melanocytes were effectively expanded; melanocytes in group B were unevenly distributed, with the number of cells greater than 120 / mm 2 The melanocyte proliferation efficiency of group A far exceeds that of group B.
[0047] Example 6 HE staining Part of the tissue engineering epidermis was cut and dewaxed to water, tissue embedded, tissue sliced, tissue sliced dewaxed to water, HE staining and dewaxed to xylene, and finally observed under a microscope and photographed. The results are as follows Fig.10 As shown, both groups A and B tissue-engineered epidermis have the layered structure of normal human epidermis.
[0048] Example 7 Endotoxin Detection The supernatant of the finished tissue engineering epidermis obtained in Example 4 was tested according to the endotoxin gel limit test specified in the Pharmacopoeia 2020 edition. The results are shown in Table 1: The endotoxin test result of the tissue engineering epidermis was negative.
[0049] Table 1 Endotoxin test results
[0050] Note: "+" indicates "positive" and "-" indicates "negative".
[0051] Example 8 Sterility Test The supernatant of the tissue engineering epidermis product obtained in Example 4 one week ago was taken and tested according to the sterility test method specified in the Pharmacopoeia 2020 edition. The results are shown in Table 2: The sterility test result of the tissue engineering epidermis was negative.
[0052] Table 2 Sterility test results
[0053] Note: "+" indicates "positive" and "-" indicates "negative".
[0054] Example 9 Mycoplasma Detection The supernatant of the tissue engineering epidermis product obtained in Example 4 was taken and operated according to the instructions of the one-step mycoplasma detection kit (purchased from Shanghai Yise Medical Technology Co., Ltd., catalog number: MD001). The test results are shown in Table 3: The tissue engineering epidermis mycoplasma test result was negative.
[0055] Table 3 Mycoplasma detection results
[0056] Note: "+" indicates "positive" and "-" indicates "negative".
[0057] In summary, 3T3-pLenti-EF1a-C- IL1α-P2A-IL15 The results of the trophoblast group with -mGFP and the trophoblast group with ordinary 3T3 cells were compared. Both human tissue-engineered epidermis have a complete layered structure of normal human epidermis, but the melanocyte content in the tissue-engineered epidermis of the former is significantly increased and more evenly distributed, which is more conducive to the uniform recoloration and beauty of vitiligo white spots.
[0058] The above description is only a preferred embodiment of the present invention. All equivalent changes and modifications made according to the scope of the patent application of the present invention should fall within the scope of the present invention.
Claims
1. A recombinant lentiviral expression vector pLenti-EF1a-C- <h2 style=";text-align:left;direction:ltr">IL1α-P2A-IL15 -mGFP, characterized in that: The recombinant lentiviral expression vector pLenti-EF1a-C- <h2 style=";text-align:left;direction:ltr"> IL1α-P2A-IL15 -mGFP is the fusion gene <h2 style=";text-align:left;direction:ltr"> IL1α-P2A-IL15 Inserted into the restriction site BamHI / NotI of the vector pLenti-EF1a-C-mGFP; The fusion gene <h2 style=";text-align:left;direction:ltr"> IL1α-P2A-IL15 The nucleotide sequence is shown in SEQ ID NO.
1.
2. The recombinant expression vector pLenti-EF1a-C- according to claim 1 <h2 style=";text-align:left;direction:ltr"> IL1α-P2A-IL15 -mGFP, characterized in that: The fusion gene <h2 style=";text-align:left;direction:ltr"> IL1α-P2A-IL15 The amino acid sequence of the encoded protein is shown in SEQ ID NO.
2.
3. A recombinant cell, characterized in that: The recombinant cell comprises the recombinant lentiviral expression vector pLenti-EF1a-C- <h2 style=";text-align:left;direction:ltr"> IL1α-P2A-IL15 -mGFP.
4. The recombinant cell according to claim 3, characterized in that: The recombinant cell is 3T3-pLenti-EF1a-C- <h2 style=";text-align:left;direction:ltr"> IL1α-P2A-IL15 -mGFP, which is a recombinant lentiviral expression vector pLenti-EF1a-C- <h2 style=";text-align:left;direction:ltr"> IL1α-P2A-IL15 -mGFP was transfected into 3T3 cells.
5. Use of the recombinant lentiviral expression vector according to any one of claims 1 to 2 and the recombinant cell according to any one of claims 3 to 4 in in vitro culture of tissue engineering epidermis.
6. A method for culturing tissue engineering epidermis in vitro, characterized in that: The method uses the recombinant cell 3T3-pLenti-EF1a-C- <h2 style=";text-align:left;direction:ltr"> IL1α-P2A-IL15 -mGFP as trophoblast cells.
